Low interferon gamma producers are better treatment responders: a two-year follow-up of interferon beta-treated multiple sclerosis patients

Abstract

As response to interferon beta (IFNB) treatment, a 50% reduction of the mean relapse rate compared to pretreatment values has been reported. However, individual responses vary considerably, ranging from no reduction in exacerbation frequency to complete suppression of relapses for at least two years. At the moment, valid predictors for IFNB response are lacking. Here we present a prospective evaluation of 33 patients with primary relapsing multiple sclerosis, who were followed for two years of IFNB treatment. A low interferon gamma (IFG) production before treatment predicted a two-year term without exacerbations in 68.8% of cases correctly, whereas a high pretreatment IFG production implied the risk of at least one relapse in the first two years in 70.6%. These preliminary results encourage further evaluation of IFG as predictor of an IFNB treatment response.

Keywords

IFNB treatment interferon gamma multiple sclerosis predictors treatment response

Get full access to this article

View all access options for this article.

References

The IFNB Multiple Sclerosis Study Group and the University of British Columbia MS/MRI Analysis Group : Interferon beta-1b in the treatment of multiple sclerosis. Final outcome of the randomized controlled trial . Neurology 1995; 45: 1277-1285 .

PRISMS Study Group . Randomized placebo-controlled double-blind study of interferon b-1a in relapsing/remitting multiple sclerosis . Lancet 1998; 352: 1498-1504 .

Jacobs LD , Cookfair DL , Rudick RA , et al. Intramuscular Interferon beta-1a for disease progression in relapsing multiple sclerosis . Ann Neurol 1996; 39: 285-294 .

The IFNB Multiple Sclerosis Study Group . Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial . Neurology 1993; 43: 655-661 .

Panitch HS , Hirsch RL , Haley AS , Johnson KP. Exacerbation of multiple sclerosis in patients treated with gamma interferon . Lancet 1987; 1: 893-895 .

Philippe J , Debruyne J , Leroux-Roels G , Willems A , Dereuck J. In vitro TNF-alpha, IL-2 and IFN-gamma production as markers of relapses in multiple sclerosis . Clin Neurol Neurosurg 1996; 98: 286-290 .

Dettke M , Scheidt P , Prange H , Kirchner H. Correlation between interferon production and clinical disease activity in patients with multiple sclerosis . J Clin Immunol 1997; 17: 293-300 .

Petereit HF , Richter N , Pukrop R , Bamborschke S. Interferon gamma production in blood lymphocytes correlates with disability score in multiple sclerosis patients . Mult Scler 2000; 6: 19-23 .

Petereit HF , Bamborschke S , Esse AD , Heiss WD. Interferon gamma producing blood lymphocytes are decreased by interferon beta therapy in patients with multiple sclerosis . Mult Scler 1997; 3: 180-183 .

10.

Rep MH , Schrijver HM , van Lopik T , et al. Interferon (IFN)-beta treatment enhances CD 95 and interleukin 10 expression but reduces interferon-gamma producing T cells in MS patients . J Neuroimmunol 1999; 96: 92-100 .

11.

Khademi M , Wallstrom E , Andersson M , Piehl F , Di Marco R , Olsson T. Reduction of both pro- and anti-inflammatory cytokines after six months of interferon beta-1a treatment of multiple sclerosis . J Neuroimmunol 2000; 103: 202-210 .

12.

Poser CM , Paty DW , Scheinberg LC , et al. New diagnostic criteria for multiple sclerosis: guidelines for research protocols . Ann Neurol 1983; 13: 227-231 .

13.

Kurtzke JF. Rating neurological impairment in multiple sclerosis: an expanded disability rating scale . Neurology 1983; 13: 1444-1452 .

14.

Crockard AD , Treacy MT , Droogan AG , McNeill TA , Hawkins SA. Transient immunomodulation by intravenous methylprednisolone treatment of multiple sclerosis . Mult Scler 1995; 1: 20-24 .

15.

Wandlinger KP , Wessel K , Trillenberg P , Heindl N , Kirchner H. Effect of high-dose methylprednisolone administration on immune functions in multiple sclerosis patients . Acta Neurol Scand 1998; 97: 359-365 .

16.

Agrawal SK , Marshall GD Jr. Dexamethasone promotes type 2 cytokine production primarily through inhibition of type 1 cytokines . J Interferon Cytokine Res 2001; 21: 147-155 .

17.

Van Boxel-Dezaire AHH , van Trigt-Hoff SCJ , Killestein J , et al.

Contrasting responses to interferon b-1b treatment in relapsing-remitting multiple sclerosis: does baseline interleukin-12p35 messenger RNA predict the efficacy of treatment?

Ann Neurol 2000; 48: 313-322 .

18.

Sinigaglia F , D’Ambrosio D , Panina-Bordignon P , Rogge L. Regulation of the IL-12/IL-12R axis: a critical step in T-helper cell differentiation and effector function . Immunol Rev 1999; 170: 65-72 .

19.

Ozenci V , Pashenkov M , Kouwenhoven M , Rinaldi L , Soderstrom M , Link H. IL-12/IL-12R system in multiple sclerosis . J Neuroimmunol 2001; 114: 242-252 .